These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 22359902)
1. [Outcome of renal transplantation after tacrolimus switch to cyclosporine]. Mesar I; Basić-Jukić N; Bubić-Filipi L; Kastelan Z; Bacak-Kocman I; Kes P Acta Med Croatica; 2011; 65(4):311-4. PubMed ID: 22359902 [TBL] [Abstract][Full Text] [Related]
2. Two-year experience with tacrolimus in renal transplantation after late conversion from cyclosporine therapy. Videla CO Transplant Proc; 2009; 41(6):2659-63. PubMed ID: 19715995 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results. Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M; Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208 [TBL] [Abstract][Full Text] [Related]
4. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF; Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978 [TBL] [Abstract][Full Text] [Related]
6. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction. Castroagudín JF; Molina E; Romero R; Otero E; Tomé S; Varo E Liver Transpl; 2009 Dec; 15(12):1792-7. PubMed ID: 19938140 [TBL] [Abstract][Full Text] [Related]
7. Increased adherence after switch from twice daily calcineurin inhibitor based treatment to once daily modified released tacrolimus in heart transplantation: a pre-experimental study. Doesch AO; Mueller S; Konstandin M; Celik S; Erbel C; Kristen A; Frankenstein L; Koch A; Dengler TJ; Ehlermann P; Zugck C; De Geest S; Katus HA Transplant Proc; 2010 Dec; 42(10):4238-42. PubMed ID: 21168673 [TBL] [Abstract][Full Text] [Related]
8. Changes in oxidative stress in renal graft patients receiving calcineurin inhibitors: cyclosporine versus tacrolimus. Akbasli AC; Keven K; Erbay B; Nebioglu S Exp Clin Transplant; 2012 Oct; 10(5):439-45. PubMed ID: 22817282 [TBL] [Abstract][Full Text] [Related]
9. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus. Fairbanks KD; Eustace JA; Fine D; Thuluvath PJ Liver Transpl; 2003 Oct; 9(10):1079-85. PubMed ID: 14526403 [TBL] [Abstract][Full Text] [Related]
10. Calcineurin inhibitor dose-finding before kidney transplantation in HIV patients. Pulzer A; Seybold U; Schönermarck U; Stangl M; Habicht A; Bogner JR; Franke J; Fischereder M Transpl Int; 2013 Mar; 26(3):254-8. PubMed ID: 23227980 [TBL] [Abstract][Full Text] [Related]
11. Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. Teutonico A; Schena PF; Di Paolo S J Am Soc Nephrol; 2005 Oct; 16(10):3128-35. PubMed ID: 16107580 [TBL] [Abstract][Full Text] [Related]
12. Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression. Hernández D; Miquel R; Porrini E; Fernández A; González-Posada JM; Hortal L; Checa MD; Rodríguez A; García JJ; Rufino M; Torres A Transplantation; 2007 Sep; 84(6):706-14. PubMed ID: 17893603 [TBL] [Abstract][Full Text] [Related]
13. Conversion from tacrolimus to cyclosporine could improve control of posttransplant diabetes mellitus after renal transplantation. Ramos-Cebrián M; Torregrosa JV; Gutiérrez-Dalmau A; Oppenheimer F; Campistol JM Transplant Proc; 2007 Sep; 39(7):2251-3. PubMed ID: 17889154 [TBL] [Abstract][Full Text] [Related]
14. Suitable calcineurin inhibitor concentrations for liver transplant recipients in the Chinese population. Chen YB; Li SD; Ju BL; Shi XJ; Lu F; Hu DK; Yu CH; Dong JH Transplant Proc; 2011 Jun; 43(5):1751-3. PubMed ID: 21693271 [TBL] [Abstract][Full Text] [Related]
15. Quantitative analysis of regulatory T cells in kidney graft recipients: a relationship with calcineurin inhibitor level. Calvo-Turrubiartes M; Romano-Moreno S; García-Hernández M; Chevaile-Ramos JA; Layseca-Espinosa E; González-Amaro R; Portales-Pérez D Transpl Immunol; 2009 May; 21(1):43-9. PubMed ID: 19233271 [TBL] [Abstract][Full Text] [Related]
16. Paired kidney analysis of tacrolimus and cyclosporine microemulsion-based therapy in Chinese cadaveric renal transplant recipients. Cheung CY; Wong KM; Chan HW; Liu YL; Chan YH; Wong HS; Chak WL; Choi KS; Chau KF; Li CS Transpl Int; 2006 Aug; 19(8):657-66. PubMed ID: 16827683 [TBL] [Abstract][Full Text] [Related]
18. Conversion from tacrolimus to cyclosporine A for new-onset diabetes after transplantation: a single-centre experience in renal transplanted patients and review of the literature. Ghisdal L; Bouchta NB; Broeders N; Crenier L; Hoang AD; Abramowicz D; Wissing KM Transpl Int; 2008 Feb; 21(2):146-51. PubMed ID: 17971033 [TBL] [Abstract][Full Text] [Related]
19. Optimizing tacrolimus therapy in the maintenance of renal allografts: 12-month results. Bolin P; Shihab FS; Mulloy L; Henning AK; Gao J; Bartucci M; Holman J; First MR; Transplantation; 2008 Jul; 86(1):88-95. PubMed ID: 18622283 [TBL] [Abstract][Full Text] [Related]
20. Low-dose calcineurin inhibitor regimen combined with mammalian target of rapamycin inhibitors preserves kidney functions in renal transplant recipients without allograft nephropathy. Kacar S; Gurkan A; Karaca C; Varılsuha C; Tilif S Transplant Proc; 2010 Nov; 42(9):3513-6. PubMed ID: 21094806 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]